Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.92 USD | +0.22% | +0.79% | +24.46% |
Apr. 12 | Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 | MT |
Apr. 08 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
Evolution of the average Target Price on Catalent, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Catalent, Inc.
Zacks Investment Research | |
UBS | |
Stephens Inc. | |
RBC Capital Markets | |
Deutsche Bank Securities | |
Barclays | |
Wells Fargo Securities | |
Baird | |
Argus | |
Morgan Stanley | |
JPMorgan Chase | |
Jefferies & Co. | |
BofA Securities | |
Nephron Research | |
William Blair & Co. | |
KeyBanc Capital Markets |
EPS Revisions
- Stock Market
- Equities
- CTLT Stock
- Consensus Catalent, Inc.